Vistagen Therapeutics, Inc. - Common Stock (NQ: VTGN )
2.850
-0.080
(-2.73%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 19, 2025
Add to My Watchlist
All News about Vistagen Therapeutics, Inc. - Common Stock
![](https://cdn.benzinga.com/files/images/story/2022/ep_us_feature_image_3416.jpeg?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20220622005431/en/1493682/4/VistaGen_logo_FINAL.jpg)
![](https://mms.businesswire.com/media/20220617005073/en/1489801/5/logo.jpg)
![](https://talkmarkets.com/images/logos/talkmarkets.png)
![](https://cdn.benzinga.com/files/images/story/2022/earnings_image_1240.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_6677.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_10371.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_10264.jpeg?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20220602005364/en/1474306/4/VistaGen_logo_FINAL.jpg)
![](https://mms.businesswire.com/media/20220527005062/en/1469055/4/VistaGen_logo_FINAL.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_9212.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_9268.jpeg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715.png)
![](https://mms.businesswire.com/media/20220502005325/en/1439296/4/VistaGen_logo_FINAL.jpg)
VistaGen Appoints Reid Adler as Chief Legal Officer
May 02, 2022
Via Business Wire
![](https://mms.businesswire.com/media/20220421005424/en/1427903/4/VistaGen_logo_FINAL%5B1%5D.jpg)
![](https://mms.businesswire.com/media/20220412005206/en/1418033/5/Affamed-Therapeutics-logo-CMYK-V-%281%29-%28002%29.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_3801.jpeg)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_2778.jpeg?width=720)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_4337.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_4242.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_2959.jpeg)
![](https://cdn.benzinga.com/files/images/story/2022/roce_image_224.jpeg?width=1200&height=800&fit=crop)
VistaGen Therapeutics Earnings Perspective: Return On Capital Employed
February 14, 2022
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.